Found 40 articles for: "tofacitinib"
Oral Lichen Planus Successfully Treated With Upadacitinib
April 2024 | Volume 23 | Issue 4 | Case Reports | e104 | Copyright © April 2024
With the rise of Janus kinase (JAK) and Signal Transducer and Activator of Transcription (STAT) inhibitor use in dermatologic conditions, there has been increasing hope in treating extensive and ...
Read MoreSurvey of the Prices of Topical Compounded Medications for Alopecia in the Tri-State Area
March 2024 | Volume 23 | Issue 3 | Original Article | 168 | Copyright © March 2024
Background: Currently, there is only one topical medication approved by the U.S. Food and Drug Administration for alopecia, minoxidil 2.5% and 5%. With limited options, dermatolo...
Read MoreNovel Clinical Applications of Topical Ruxolitinib: A Case Series
March 2024 | Volume 23 | Issue 3 | Case Reports | 188 | Copyright © March 2024
Topical ruxolitinib, a potent Janus kinase (JAK) inhibitor, has shown significant efficacy in treating inflammatory skin conditions. While its use has already been established in atopic dermatiti...
Read MoreA Case Series of TNF Inhibitor-Induced Psoriasis Successfully Treated With Upadacitinib
February 2024 | Volume 23 | Issue 2 | Case Reports | e60 | Copyright © February 2024
Tumor necrosis factor-alpha inhibitors (TNF-i) are commonly used to treat immune-mediated diseases such as psoriasis, psoriatic arthritis (PsA), inflammatory bowel disease (IBD), spondyloarthriti...
Read MorePost-Hyaluronic Acid Filler Reaction Treated With Abrocitinib: A Case Report
January 2024 | Volume 23 | Issue 1 | Case Reports | 1355 | Copyright © January 2024
Post-hyaluronic acid filler nodules are uncommon, unpredictable complications that present a challenge to clinical therapy. We report a case of a female in her fifties who developed edema and nod...
Read MoreDeucravacitinib for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
February 2024 | Volume 23 | Issue 2 | Original Article | 67 | Copyright © February 2024
There is contrasting evidence regarding the efficacy and safety of JAK (Janus kinase) inhibitors in the treatment of psoriasis. This systematic review and meta-analysis assessed deucravacitinib, ...
Read MoreOff-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Diseases
December 2023 | Volume 22 | Issue 12 | Original Article | 1183 | Copyright © December 2023
Dysregulation of Janus kinase (JAK) pathways from uncontrolled cytokine signaling comprises the pathological basis for many complex inflammatory cutaneous disorders. Oral JAK inhibitors, upadacit...
Read MoreINDIVIDUAL ARTICLE: Management of Prurigo Nodularis
December 2023 | Volume 22 | Issue 12 | Supplement Individual Articles | SF365502s15 | Copyright © December 2023
Background: Prurigo nodularis (PN) is a chronic disease characterized by intense pruritus and nodular lesions associated with reduced quality of life. Until recently, no US Food ...
Read MoreA Review of the Current Landscape of Hidradenitis Suppurativa Treatment Development
October 2023 | Volume 22 | Issue 10 | Original Article | 1021 | Copyright © October 2023
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by recurrent nodules and abscesses leading to subsequent scarring and tunnel form...
Read MoreAlopecia Areata: The Clinician and Patient Voice
October 2023 | Volume 22 | Issue 10 | Original Article | 967 | Copyright © October 2023
Alopecia areata (AA), an autoimmune disorder of hair follicles, results in varying degrees of scalp, facial, and body hair loss. In addition, it is associated with profound psychosocial and quali...
Read MoreOff-Label Use of Baricitinib in Dermatology
August 2023 | Volume 22 | Issue 8 | Original Article | 795 | Copyright © August 2023
The current US Food and Drug Administration (FDA) indications for baricitinib include alopecia areata, rheumatoid arthritis, and COVID-19. However, increasing evidence indicates that baricitinib ...
Read MoreOpen-Label Phase 2 Pilot Study of Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE)
April 2023 | Volume 22 | Issue 4 | Features | 425 | Copyright © April 2023
Citation: Alsukait S, Learned C, Rosmarin D. Open-label phase 2 pilot study of oral tofacitinib in adult subjects with Discoid Lupus Erythematosus (DLE). J Drugs Dermatol. 2023;22(4)...
Read MoreWATCH VIDEO ABSTRACT: Scarring and Dyschromias in Fitzpatrick Skin Type IV-VI: A Review of Dermatologic Treatment Protocols
March 2023 | Volume 22 | Issue 3 | Original Article | 288 | Copyright © March 2023
Read MoreScarring and Dyschromias in Fitzpatrick Skin Type IV-VI: A Review of Dermatologic Treatment Protocols
July 2023 | Volume 22 | Issue 7 | Original Article | 7253 | Copyright © July 2023
Importance: Managing chronic conditions is an essential aspect of dermatologic care, especially regarding the resolution of inflammatory dermatologic disease and recovery of skin lesi...
Read MoreOff-Label Uses of JAK Inhibitors in Dermatology
October 2022 | Volume 21 | Issue 10 | Features | 1143 | Copyright © October 2022
The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway is a crucial component of immune function, and JAK inhibitors allow dermatologists to regulate this pathway in ce...
Read MoreJAK Inhibitor Safety Compared to Traditional Systemic Immunosuppressive Therapies
December 2022 | Volume 21 | Issue 12 | Original Article | 1298 | Copyright © December 2022
Dermatologists treating atopic dermatitis are interested in the safety profile of the recently available JAK inhibitors, upadacitinib and abrocitinib, especially after they received boxed safety warni...
Read MoreRefractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy
December 2022 | Volume 21 | Issue 12 | Case Reports | 1366 | Copyright © December 2022
Background: In the last several years, oral tofacitinib has become an increasingly utilized off-label treatment option for immune-mediated skin conditions such as alopecia areata (AA)...
Read MoreA Retrospective Review of Tofacitinib in the Treatment of Refractory Dermatomyositis
October 2022 | Volume 21 | Issue 10 | Editorials | 1133 | Copyright © October 2022
Dermatomyositis (DM) is an autoimmune myopathy with characteristic dermatologic features.1 Tofacitinib is an immunomodulator with proven efficacy against numerous immune-mediated disorders,...
Read MoreNew Biologics and Oral Drugs in Treatment of Moderate to Severe Psoriasis
August 2022 | Volume 21 | Issue 8 | Original Article | 826 | Copyright © August 2022
Psoriasis is known to have no definitive cure, which is in common with other inflammatory disorders. Various treatment options are available, and they help in decreasing the disease activity and impro...
Read MoreNail Psoriasis Improvement During Tildrakizumab Therapy: A Real-Life Experience
August 2022 | Volume 21 | Issue 8 | Editorials | 914 | Copyright © August 2022
The aim of this retrospective study of patients affected by plaque psoriasis who underwent tildrakizumab therapy was to describe and compare the response of the nail psoriasis and the plaque psoriasis...
Read MoreMedia and other results for: "tofacitinib"
© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
